Compare VRAR & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAR | ITRM |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 24.3M |
| IPO Year | 2021 | 2018 |
| Metric | VRAR | ITRM |
|---|---|---|
| Price | $0.94 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.62 | ★ $9.00 |
| AVG Volume (30 Days) | 105.4K | ★ 1.0M |
| Earning Date | 11-13-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,488,209.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | $325.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.60 | N/A |
| 52 Week Low | $0.89 | $0.36 |
| 52 Week High | $7.00 | $2.10 |
| Indicator | VRAR | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 36.53 |
| Support Level | $1.03 | $0.44 |
| Resistance Level | $1.16 | $0.49 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 2.52 | 1.35 |
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.